Johnson & Johnson
Prix: 240.87Entreprise et modèle économique
Johnson & Johnson is a global healthcare company that develops and manufactures a wide range of products across three major segments: Pharmaceuticals, Medical Devices, and Consumer Health. Its core products include prescription medications, surgical instruments, and consumer health products such as over-the-counter drugs and personal care items. The company generates revenue primarily from its pharmaceutical segment, which includes treatments for various diseases, followed by medical devices and consumer health products.
Profil d’investissement
Johnson & Johnson presents a balanced investment profile, appealing to investors seeking a combination of growth and dividends. The company has a stable dividend yield, indicating a commitment to returning value to shareholders. Its diversified business segments provide resilience against market fluctuations, making it suitable for medium to long-term investment horizons.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 8.67 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -2.0% ↓
- Surprise BPA
- 0.7% conforme
- Volatilité 20 j
- 1.2% stable
- Rendement du dividende
- 2.3% modéré dernière date ex-dividende: 2026-05-26
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-10 00:46 | Conserver | Acheter | Strong momentum and solid dividend yield support growth. |
| 2026-05-30 02:42 | Acheter | Conserver | Weak momentum and fundamentals raise uncertainty. |
| 2026-05-22 02:50 | Conserver | Acheter | Stable dividends, but mixed momentum signals present uncertainty. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-13 10:04 | Leerink Partners | Note relevée | — → 265 | 224.26 |
| 2026-04-20 12:24 | Guggenheim | Objectif relevé | 244 → 266 | 232.71 |
| 2026-04-15 12:31 | Morgan Stanley | Objectif relevé | 267 → 283 | 239.66 |